Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 55Pancreatic Neoplasms 14Colorectal Neoplasms 6Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Esophageal Neoplasms 4Biliary Tract Neoplasms 4Advanced Pancreatic Cancer 3Stage IV Gastric Cancer With Metastasis 2Recurrence 2Rectal Neoplasms 2Locally Advanced Pancreatic Cancer 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Gastric Cancer 2mCRC 1Surgically-Created Resection Cavity 1Radiation Injuries 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Ductal Adenocarcinoma 1Non-small Cell Lung Cancer Stage â…¡ 1Nasopharyngeal Carcinoma 1NSCLC 1Metastatic Gastric Adenocarcinoma 1Lung Neoplasms 1HER2-positive 1HER-2 Negatived Gastric Cancer 1Gastric Cancer With Positive Exfoliative Cancer Cells 1

Interventions

camrelizumab 2apatinib 2S 1 (combination) 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Metastatic Gastric Adenocarcinoma × S 1 (combination) × Clear all
NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Zhongnan Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡